SYM FINANCIAL Corp Has $357,000 Stake in Gilead Sciences, Inc. $GILD

SYM FINANCIAL Corp boosted its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 69.4% in the second quarter, HoldingsChannel.com reports. The firm owned 3,217 shares of the biopharmaceutical company’s stock after buying an additional 1,318 shares during the period. SYM FINANCIAL Corp’s holdings in Gilead Sciences were worth $357,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Southland Equity Partners LLC increased its holdings in Gilead Sciences by 2.9% in the second quarter. Southland Equity Partners LLC now owns 3,285 shares of the biopharmaceutical company’s stock valued at $364,000 after purchasing an additional 92 shares during the period. Twelve Points Wealth Management LLC increased its holdings in Gilead Sciences by 1.5% in the second quarter. Twelve Points Wealth Management LLC now owns 6,499 shares of the biopharmaceutical company’s stock valued at $721,000 after purchasing an additional 98 shares during the period. Argentarii LLC increased its holdings in Gilead Sciences by 3.0% in the first quarter. Argentarii LLC now owns 3,392 shares of the biopharmaceutical company’s stock valued at $380,000 after purchasing an additional 99 shares during the period. Lodestar Private Asset Management LLC increased its holdings in Gilead Sciences by 3.6% in the first quarter. Lodestar Private Asset Management LLC now owns 2,840 shares of the biopharmaceutical company’s stock valued at $318,000 after purchasing an additional 100 shares during the period. Finally, Advantage Trust Co increased its holdings in Gilead Sciences by 13.6% in the second quarter. Advantage Trust Co now owns 838 shares of the biopharmaceutical company’s stock valued at $93,000 after purchasing an additional 100 shares during the period. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences Price Performance

GILD stock opened at $120.47 on Tuesday. The stock has a market capitalization of $149.48 billion, a PE ratio of 24.00, a price-to-earnings-growth ratio of 0.83 and a beta of 0.34. The company’s 50-day moving average is $115.52 and its 200-day moving average is $111.21. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.32 and a quick ratio of 1.15. Gilead Sciences, Inc. has a 1 year low of $86.08 and a 1 year high of $124.61.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.96 by $0.05. The company had revenue of $7.08 billion for the quarter, compared to analysts’ expectations of $6.95 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The business’s revenue was up 1.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.01 EPS. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Equities research analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Insider Transactions at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction dated Wednesday, October 15th. The shares were sold at an average price of $118.08, for a total transaction of $295,200.00. Following the transaction, the chief financial officer owned 157,055 shares of the company’s stock, valued at $18,545,054.40. This represents a 1.57% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Daniel Patrick O’day sold 10,000 shares of the stock in a transaction dated Monday, September 29th. The stock was sold at an average price of $111.66, for a total transaction of $1,116,600.00. Following the transaction, the chief executive officer directly owned 591,203 shares in the company, valued at $66,013,726.98. This trade represents a 1.66% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 61,500 shares of company stock valued at $7,142,140 in the last 90 days. 0.27% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

GILD has been the subject of a number of recent research reports. Weiss Ratings restated a “buy (b)” rating on shares of Gilead Sciences in a report on Wednesday, October 8th. Royal Bank Of Canada upped their price target on shares of Gilead Sciences from $98.00 to $100.00 and gave the company a “sector perform” rating in a research report on Wednesday, October 8th. The Goldman Sachs Group upped their price target on shares of Gilead Sciences from $105.00 to $108.00 and gave the company a “neutral” rating in a research report on Friday, October 17th. Needham & Company LLC raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $133.00 price target on the stock in a research report on Friday, July 25th. Finally, Truist Financial raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and upped their price target for the company from $108.00 to $127.00 in a research report on Friday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $122.61.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.